| Identification | Back Directory | [Name]
Tulopafant | [CAS]
116289-53-3 | [Synonyms]
Tulopafant
1H,3H-Pyrrolo[1,2-c]thiazole-7-carboxamide, N-(3-benzoylphenyl)-3-(3-pyridinyl)-, (+)- | [Molecular Formula]
C25H19N3O2S | [MDL Number]
MFCD00865280 | [MOL File]
116289-53-3.mol | [Molecular Weight]
425.5 |
| Chemical Properties | Back Directory | [Boiling point ]
613.3±55.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
13.51±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
Tulopafant is a platelet activating factor (PAF) antagonist. | [in vivo]
Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs[1].Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant[2]. | [storage]
Store at -20°C | [References]
[1] Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998 Oct;93(5):361-71. DOI:10.1007/s003950050104
[2] O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84. PMID:8395256 |
|
|